A Phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM)
Volker W. Stieber(Southeast Clinical Oncology Research Consortium), Edward Shaw(Wake Forest University), James Lovato(Wake Forest University), Constance A. Stanton(Wake Forest University), A.F. deGuzman(Wake Forest University), R. Rosdahl(Wake Forest University), W.T. Kearns(Radiation Oncology Associates), J. Daniel Bourland(Radiation Oncology Associates), Thomas L. Ellis(Wake Forest University), Glenn J. Lesser(Virginia Commonwealth University), William H. Hinson(Wake Forest University), Stephen B. Tatter(Atrium Health Wake Forest Baptist)
International Journal of Radiation Oncology*Biology*Physics
September 1, 2004
Cited by 13
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05
|International Journal of Radiation Oncology*Biology*Physics|2000|1.6k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
|Journal of Clinical Oncology|2006|725
Subsecond dopamine fluctuations in human striatum encode superposed error signals about actual and counterfactual reward
|Proceedings of the National Academy of Sciences|2015|239